BioSpace News Archive

ARGEN-LT delivers the only continuous stability measurement for shelf-life studies at low temperature(s).

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its full year 2021 financial results after market close on Thursday, March 10, 2022.

Xencor, Inc. reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a review of recent business and clinical highlights.

BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other cough hypersensitivity indications, reported its financial and operating results for the year ending December 31, 2021.

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter and full year ended December 31, 2021.

Certara, Inc. today announced that the U.S. Food and Drug Administration (FDA) has licensed Certara’s Immunogenicity (IG) Simulator to research and evaluate immunogenicity in protein-based therapeutics. Certara’s IG Simulator predicts the immune response of therapeutics in development, which is important to guide clinical and regulatory decision-making.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the peer-reviewed journal Psychiatry Research has published a new analysis of GeneSight® Psychotropic, the company’s mental health medication test, in its Feb. 2022 edition.

Quanterix Corporation today announced that it will release its financial results for fourth quarter 2021 before the start of trading on Tuesday, March 1, 2022.

Blue Water Vaccines Inc., a biopharmaceutical company developing vaccines, announced the closing of its initial public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share.

Thermo Fisher Scientific Inc., the world leader in serving science, announced Ruby Chandy has been elected to its board of directors, effective March 1, 2022.